Medtide Inc. (HKG:3880) took in HK$428.8 million in net proceeds from its initial public offering in Hong Kong after pricing the shares at the top end of the indicative price range.
The peptide-focused CRDMO priced the IPO shares at HK$30.60 apiece, the upper limit of the price guidance of as low as HK$28.40, according to a Friday after-market hours filing.
The Hong Kong public offer portion of the deal was 301.15 times subscribed, triggering the reallocation of 6,720,000 shares from the international offering and taking the total number of shares offered under this tranche to 8,400,000 from 1,680,000 initially.
The international offering was 2.43 times subscribed and the company issued 8,400,000 shares, reduced from 15,120,000 shares initially following the reallocation.
Medtide will make its trading debut on the Hong Kong bourse Monday, June 30.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。